Virbac licenses MabGenesis’ therapeutic antibodies for canine diseases
2025/04/16 - Financial public releases
Discover the press release issued on April 16, 2025.
Virbac licenses MabGenesis’ therapeutic antibodies for canine diseases
2025/04/16 - Financial public releases
Discover the press release issued on April 16, 2025.
2025 first quarter consolidated sales
2025/04/15 - Financial public releases
2024 annual results
2025/03/13 - Financial public releases
● 2024 operating income2 at an all-time high of 16.6% of revenues (16.0% excluding
acquisitions)
○ up by 1.5 percentage points compared to 2023
● Positive trend for 2025
○ sales growth expected between 4% and 6% at constant exchange rates and scope
○ operating income relatively stable at around 16%, excluding the impact of acquisitions
Annual Ordinary General Meeting
From 2025/06/19
Annual Ordinary General Meeting
2025 second quarter sales
From 2025/07/16
2025 second quarter sales
(quiet period from July 2, 2025)
2025 interim result
From 2025/09/12
2025 interim result
(quiet period from August 15, 2025)
2025 first quarter sales
From 2025/04/15
2025 first quarter sales
(quiet period from April 1, 2024)
SFAF meeting - 2024 financial & strategic information
From 2025/03/14
2024 results
From 2025/03/13
2024 results
(quiet period from February 13, 2025)